Gliomas are primary tumors of the central nervous system that affect individuals of all ages. Staggering 5-year survival rates of 5%–10% for the most aggressive high-grade glioma, glioblastoma, led to intensive research on tumor biology and the microenvironment (Miller et al., 2021; Girardi et al., 2023; Schaff and Mellinghoff, 2023).
Recent advances in research techniques revealed the highly heterogenous nature of these tumors and complex interactions of all cells within the tumor microenvironment (Chen and Hambardzumyan, 2018; Neftel et al., 2019; Varn et al., 2022; Walentynowicz et al., 2023).
A wealth of transcriptomic, genetic, proteomic, and clinical information has been made available via public databases such as The Cancer Genome Atlas (TCGA) or The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC), providing valuable resources for data analysis and identification of novel signatures relevant to human cancers, including glioma. This Research Topic includes three original research articles and two reviews covering broad Research Topic of glioma biology. Emerging Research Topic in 7-methylguanosine (m7G) regulators and their association with cancer, immunogenic cell death mechanisms, and senescence in glioma were studied to identify transcriptomic signatures.
Wang et al. reports a novel signature of m7G regulators that correlates with the immune microenvironment and carries prognostic value in high-grade and low-grade glioma patients. Using selected differentially expressed m7G regulators in high-grade glioma (NUDT5, EIF4E1B, and NUDT11) and low-grade glioma (CYFIP1, CYFIP2, EIF3D, GEMIN5, NUDT5, NUDT1, and EIF4E3), a prognostic signature was computed. EIF4E1B expression was found to correlate with alternative splicing events in both high- and low-grade tumors. Higher expression of immune checkpoint genes and HLA genes was associated with the high-risk group in both tumor grades, following application of the m7G signature.
Cai et al. found immunogenic cell death (ICD)-associated biomarkers that correlate with survival, immune score, and treatment response in low-grade glioma. ICD genes were found to be significantly upregulated in low-grade gliomas compared to normal brain samples. Gene signatures associated with ICD were calculated by GeneMANIA and subsequent clustering identified groups that significantly associated with immune pathway enrichment, immune score, and clinicopathological features. Both ICD-low and high groups harbored high incident of somatic mutations in IDH1, TP53 and ATRX, with higher incident of CIC (26.3% vs. 13.2%) in ICD-low and TTN in ICD high (16.7% vs. 9.5%). The ICD-high group has poorer prognosis but showed higher predicted drug sensitivity compared to the ICD-low group.
Li et al. looked at senescence-related genes in low- and high-grade gliomas, identifying six genes (AURKA, CENPA, LIMK1, PATZ1, TGFB1I1, TLR3) associated with significant survival benefit that could be used in a regression model to predict prognostic ‘risk’ in low-grade glioma. The high-risk group showed enrichment in major glioma over-represented pathways like TNFα signaling via NFκB, epithelial mesenchymal transition, IL6/JAK/STAT3 pathway according to Gene Set Enrichment Analysis. Tumors with a high senescence score were enriched, overall, for immune-cell marker genes, suggesting higher immune infiltration, and had higher expression of immune checkpoint genes like PD1, PDL1, and TIM3. The authors then validated their senescence signature in various glioma samples containing public datasets, confirming that lower senescence signature risk scores significantly associated with survival benefit.
Lastly, two review articles focused on epigenetic dysregulation in glioma. Liu et al. described the impact of long non-coding RNAs (lncRNAs) in glioma progression, as multiple lncRNAs are identified as aberrantly expressed in malignant tumors. Groves and Cooney focused on epigenetic modifications identified in pediatric high-grade glioma and epigenetic therapeutic modalities.
In summary, this Research Topic encompasses focused analysis on gene expression signatures in glioma with potential clinical impact, stratifying patients into various subgroups. It provides an overview of the current state of epigenetic modifying therapies for pediatric gliomas, and the impact of lncRNAs on glioma progression.
Funding Statement
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Author contributions
KW: Project administration, Writing–original draft, Writing–review and editing. LS: Writing–review and editing. AE-M: Writing–review and editing. KK: Writing–review and editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
- Chen Z., Hambardzumyan D. (2018). Immune microenvironment in glioblastoma subtypes. Front. Immunol. 9. 10.3389/fimmu.2018.01004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Girardi F., Matz M., Stiller C., You H., Gragera R. M., Valkov M. Y., et al. (2023). Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000–2014 (CONCORD-3). Neuro Oncol. 25, 580–592. 10.1093/NEUONC/NOAC217 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Miller K. D., Ostrom Q. T., Kruchko C., Patil N., Tihan T., Cioffi G., et al. (2021). Brain and other central nervous system tumor statistics, 2021. CA Cancer J. Clin. 71, 381–406. 10.3322/CAAC.21693 [DOI] [PubMed] [Google Scholar]
- Neftel C., Laffy J., Filbin M. G., Hara T., Shore M. E., Rahme G. J., et al. (2019). An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835–849.e21. 10.1016/j.cell.2019.06.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schaff L. R., Mellinghoff I. K. (2023). Glioblastoma and other primary brain malignancies in adults: a review. JAMA 329, 574–587. 10.1001/JAMA.2023.0023 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Varn F. S., Johnson K. C., Martinek J., Huse J. T., Nasrallah M. P., Wesseling P., et al. (2022). Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell 185, 2184–2199.e16. 10.1016/J.CELL.2022.04.038 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Walentynowicz K. A., Engelhardt D., Cristea S., Yadav S., Onubogu U., Salatino R., et al. (2023). Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma. Cell Rep. 42, 112235. 10.1016/J.CELREP.2023.112235 [DOI] [PMC free article] [PubMed] [Google Scholar]